Brain Insulin Resistance in Mood Disorders

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

October 5, 2024

Study Completion Date

October 5, 2024

Conditions
Major Depressive DisorderBipolar DisorderAnhedoniaIntranasal Insulin
Interventions
DRUG

Humulin R

"The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."

DRUG

Diluent

"The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."

Trial Locations (1)

M5T2S8

RECRUITING

Toronto Western Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER